Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy

European Journal of Heart Failure

Volumn 4, Issue 4, 2002, Pages 439-444

  Schwartzkopff, Bodo ^a   Fassbach, Michael ^a   Pelzer, Beate ^a   Brehm, Michael ^a   Strauer, Bodo E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Collagenases; Dilated cardiomyopathy; LV dilation; Matrix metalloproteinases; Ventricular remodelling

Indexed keywords

COLLAGEN; COLLAGENASE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; INTERSTITIAL COLLAGENASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEROLOGY; BLOOD; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; ENZYMOLOGY; HEART MUSCLE; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; COLLAGEN; COLLAGENASES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYOCARDIUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0036672897     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00092-2     Document Type: Article

References (38)

1. Andersson B, Caidahl K, Waagstein F, Olofsson EL. Idiopathic dilated cardiomyopathy among Swedish patients with congestive heart failure. Eur Heart J 1995;16:53-60.
2. Brilla CG, Maisch B, Zhou G, Weber KT. Hormonal regulation of cardiac fibroblast function. Eur Heart J 1995;16 Suppl. C:45-50.
3. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Am J Pathol 1996;148:1639-48.
4. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998;82:482-95.
5. Weber KT, Pick R, Silver MA, et al. Fibrillar collagen and remodelling of dilated canine left ventricle. Circulation 1990;82:1387-401.
6. Dolley CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-8.
7. Nagase H. Activation mechanisms of matrix metalloproteinases. Review. J Biol Chem 1997;378:151-60.
8. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodelling of the extracellular matrix. Am J Pathol 1996;148:1345-50.
9. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of Rheumatology. New York, NY: WB Saunders, 1993. p. 248-68.
10. Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45.
11. Weber KT, Brilla CG. Pathological hypertrohy and cardiac interstitium: fibrosis and renin-angiotensin-aldosteron system. Circulation 1991;83:1849-65.
12. Tyagi SC, Kumar SG, Banks J, Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol 1995;27(10):2177-89.
13. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, non-infarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 1996;155:13-21.
14. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 1999;85(4):364-76.
15. Hirohata S, Kusachi S, Murakami M, et al. Time dependent alterations of serum matrix metalloproteinase-2 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997;78(3):278-84.
16. Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98(6):535-40.
17. Cohn JN, Tognoni G. Effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2001;102(21):2672.
18. Johnson RA, Palacios I. Dilated cardiomyopathies of the adult. N Engl J Med 1982;307:1051-8.
19. Weber KT, Anversa P, Armstrong PW, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992;20:3-16.
20. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944-9.
21. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley 3rd AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation May 5, 1998;975(17):1708-15.
22. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem Nov 1, 1996;63(2):185-98.
23. Yokoseki O, Yazaki Y, Imamura H, Takenaka H, Isobe M. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy. Jpn Circ J 2000;64(5):352-7.
24. Pachinger O, Kliepera M, Sochor H, et al. Hämodynamik der kongestiven Kardiomyopathie. Z Kardiol 1982;71:509-16.
25. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994;331(23):1564-75.
26. Hayward CS, Webb CM, Collins P. Effect of sex hormones on cardiac mass. Lancet 2001;357(9265):1354-6.
27. Singer CF, Marbaix E, Kokorine I, et al. The matrix metalloproteinase-1 (MMP-1) expression in the human endometrium is inversely regulated by interleukin-1 alpha and sex steroids. Ceska Gynekol 2000;65(4):211-5.
28. Pauschinger M, Knopf D, Petschauer F, et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 1999;99:2750-6.
29. Klappacher G, Franzen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol May 1, 1995;75(14):913-8.
30. Marriott JB, Goldman JH, Keeling PJ, Baig MK, Dalgleish AG, McKenna WJ. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 1996;75:287-90.
31. Munger MA, Johnson B, amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77(9):723-7.
32. Overall CM. Regulation of tissue inhibitor of matrix metalloproteinase expression. Ann NY Acad Sci 1994;732:51-64.
33. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation to bone histomorphometry. J Bone Miner Res 1993;8:127-32.
34. Jensen LT, Olesen HP, Risteli J, Lorenzen I. External thoracic duct-venous shunt in conscious pigs for long term studies of connective tissue metabolites in lymph. Lab Anim Sci 1990;40:620-4.
35. Dixon IM, Ju H, Reid NL, Scammell-La Fleur T, Werner JP, Jasmin G. Cardiac collagen remodelling in the cardiomyopathic Syrian hamster and the effect of losartan. J Mol Cell Cardiol 1997;29(7):1837-50.
36. Li H, Simon H, Bocan TM, Peterson JT. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 2000;46(2):298-306.
37. Senzaki H, Paolocci N, Gluzband YA, et al. Beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res 2000;86(7):807.
38. Grimm D, Huber M, Jabusch HC, et al. Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade. J Mol Cell Cardiol 2001;33(3):487-501.